Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catheter Precision (VTAK) Notes Payables (2020 - 2025)

Catheter Precision has reported Notes Payables over the past 5 years, most recently at $306000.0 for Q4 2025.

  • Quarterly Notes Payables fell 80.88% to $306000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $306000.0 through Dec 2025, down 80.88% year-over-year, with the annual reading at $306000.0 for FY2025, 80.88% down from the prior year.
  • Notes Payables was $306000.0 for Q4 2025 at Catheter Precision, up from $303000.0 in the prior quarter.
  • Over five years, Notes Payables peaked at $14.2 million in Q2 2023 and troughed at $7592.0 in Q1 2023.
  • The 4-year median for Notes Payables is $306000.0 (2025), against an average of $3.0 million.
  • The largest YoY upside for Notes Payables was 769.57% in 2024 against a maximum downside of 98.24% in 2024.
  • A 4-year view of Notes Payables shows it stood at $674000.0 in 2021, then crashed by 72.7% to $184000.0 in 2023, then soared by 769.57% to $1.6 million in 2024, then tumbled by 80.88% to $306000.0 in 2025.
  • Per Business Quant, the three most recent readings for VTAK's Notes Payables are $306000.0 (Q4 2025), $303000.0 (Q3 2025), and $1.3 million (Q2 2025).